Putnam FL Investment Management Co. Buys 464 Shares of Charles River Laboratories Intl. Inc (CRL)

Putnam FL Investment Management Co. boosted its stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 0.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,897 shares of the medical research company’s stock after purchasing an additional 464 shares during the quarter. Putnam FL Investment Management Co. owned approximately 0.18% of Charles River Laboratories Intl. worth $11,960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of CRL. NumerixS Investment Technologies Inc purchased a new stake in Charles River Laboratories Intl. during the 2nd quarter worth about $122,000. Wsfs Capital Management LLC purchased a new stake in Charles River Laboratories Intl. during the 2nd quarter worth about $203,000. CIBC Private Wealth Group LLC purchased a new stake in Charles River Laboratories Intl. during the 2nd quarter worth about $212,000. Dynamic Technology Lab Private Ltd purchased a new stake in Charles River Laboratories Intl. during the 2nd quarter worth about $212,000. Finally, CIBC Asset Management Inc purchased a new stake in Charles River Laboratories Intl. during the 3rd quarter worth about $226,000. Institutional investors own 95.11% of the company’s stock.

In related news, Director Deborah Turner Kochevar sold 4,066 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total value of $502,801.56. Following the completion of the sale, the director now directly owns 10,190 shares of the company’s stock, valued at approximately $1,260,095.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Ross Smith sold 1,866 shares of the company’s stock in a transaction dated Monday, November 12th. The shares were sold at an average price of $134.49, for a total value of $250,958.34. Following the completion of the sale, the insider now directly owns 12,341 shares of the company’s stock, valued at $1,659,741.09. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,288 shares of company stock valued at $3,930,176. Insiders own 2.10% of the company’s stock.

Shares of NYSE CRL traded up $0.84 during trading hours on Monday, reaching $128.24. The stock had a trading volume of 771 shares, compared to its average volume of 398,447. The stock has a market cap of $6.13 billion, a PE ratio of 24.36, a price-to-earnings-growth ratio of 1.79 and a beta of 0.74. The company has a quick ratio of 1.32, a current ratio of 1.55 and a debt-to-equity ratio of 1.32. Charles River Laboratories Intl. Inc has a fifty-two week low of $96.70 and a fifty-two week high of $138.89.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, November 7th. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.38 by $0.15. The firm had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. Charles River Laboratories Intl. had a return on equity of 25.08% and a net margin of 6.39%. The business’s revenue was up 26.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.30 EPS. Sell-side analysts anticipate that Charles River Laboratories Intl. Inc will post 5.92 earnings per share for the current year.

Several research analysts have recently issued reports on CRL shares. Argus upped their price objective on Charles River Laboratories Intl. from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, August 27th. ValuEngine raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research report on Tuesday, September 11th. Jefferies Financial Group upped their price objective on Charles River Laboratories Intl. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. SunTrust Banks upped their price objective on Charles River Laboratories Intl. to $135.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Finally, Royal Bank of Canada set a $147.00 price objective on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $130.56.

ILLEGAL ACTIVITY WARNING: This piece of content was published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/26/putnam-fl-investment-management-co-buys-464-shares-of-charles-river-laboratories-intl-inc-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Compound Interest

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply